| (USD) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 60.14M | — |
| Operating expense | — | — |
| Net income | 2.83M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, MLAB returned +72.3% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +59.4% |
| 1 year | +72.3% |
| 5 years | -52.1% |
| 10 years | +15.7% |
| All-time high | $328.09 (Dec 2021) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what $1,000 in MLAB would be worth today ›Yes. Mesa Laboratories, Inc. paid 4 dividends over the past 12 months. The most recent was $0.16 per share on May 29, 2026. The dividend yield is 0.51%.
Mesa Laboratories, Inc. stock trades on NASDAQ under the ticker symbol MLAB.
Mesa Laboratories, Inc. is part of the Technology sector.
Mesa Laboratories, Inc. has a market cap of 698.14M USD, based on the latest quote.
Mesa Laboratories, Inc. is scheduled to report earnings on Nov 5, 2026.
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides sterility assurance testing and laboratory services to the dental and pharmaceutical industries. The Biopharmaceutical Development segment develops, manufactures, sells, and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for hereditary disease screenings, pharmacogenetics, oncology related applications, and toxicology research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; and PurePep Symphony and Chorus instruments for peptide synthesis. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as renal care, gas flow, environmental and process monitoring, and torque testing in pharmaceutical, laboratory, medical device, manufacturing, industrial, and environmental applications. This segment's products include continuous monitoring systems, data loggers, and torque testing systems under the DialyGuard, DryCal, DataTrace, and ViewPoint brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
